Contact
Score Calculators
Publications
Advancing knowledge in chronic liver disease through evidence-based research.
AbstractsPublication policy

Showing 10 of 268 papers

Systemic inflammation and acute-on-chronic liver failure: Too much, not enough

Laleman W, Claria J, Van der Merwe S, Moreau R, Trebicka J.

Can J Gastroenterol Hepatol 2018, 2018: 1027152

DOI: 10.1155/2018/1027152

Covered transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: Looking for the right patient and the right time

Senzolo M, Thabut D, Trebicka J.

EMJ Hepatol 2018, 6(Suppl 2): 2 –11

DOI: 10.33590/emjhepatol/10311962

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats

Schwabl P, Brusilovskaya K, Supper P, Bauer D, Königshofer P, Riedl F, Hayden H, Fuchs CD, Stift J, Oberhuber G, Aschauer S, Bonderman D, Gnad T, Pfeifer A, Uschner FE, Trebicka J, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Trauner M, Reiberger T.

Sci Rep 2018, 8(1): 9372

DOI: 10.1038/s41598-018-27656-y

The use of human albumin in patients with cirrhosis: A European survey

Caraceni P, Pavesi M, Baldassarre M, Bernardi M, Arroyo V.

Expert Rev Gastroenterol Hepatol 2018, 12(6): 625–632

DOI: 10.1080/17474124.2018.1460203

Managing portal hypertension in patients with liver cirrhosis

Sauerbruch T, Schierwagen R, Trebicka J.

F1000Res 2018 , 7: F1000 Faculty Rev-533

DOI: 10.12688/f1000research.13943.1

Acute-on-chronic liver failure, human serum albumin, and immune modulation: The beginning of an exciting adventure

Arroyo V, Clària J.

Clin Gastroenterol Hepatol 2018, 16(5): 633–636

DOI: 10.1016/j.cgh.2017.12.008

Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis

Simón-Talero M, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, Llop E, Praktiknjo M, Maurer MH, Zipprich A, Triolo M, Vangrinsven G, Garcia-Martinez R, Dam A, Majumdar A, Picón C, Toth D, Darnell A, Abraldes JG, Lopez M, Kukuk G, Krag A, Bañares R, Laleman W, La Mura V, Ripoll C, Berzigotti A, Trebicka J, Calleja JL, Tandon P, Hernandez-Gea V, Reiberger T, Albillos A, Tsochatzis EA, Augustin S, Genescà J; Baveno VI-SPSS group from the Baveno Cooperation

Gastroenterology 2018, 154(6): 1694–1705.e4

DOI: 10.1053/j.gastro.2018.01.028

Fibroblast growth factor 21 is an early predictor of acute-on-chronic liver failure in critically ill patients with cirrhosis

Ruiz-Margáin A, Pohlmann A, Ryan P, Schierwagen R, Chi-Cervera LA, Jansen C, Mendez-Guerrero O, Flores-García NC, Lehmann J, Torre A, Macías-Rodríguez RU, Trebicka J.

Liver Transpl 2018, 24(5): 595–605

DOI: 10.1002/lt.25041

Severe abnormal heart rate turbulence onset is associated with deterioration of liver cirrhosis

Jansen C, Al-Kassou B, Lehmann J, Pohlmann A, Chang J, Praktiknjo M, Nickenig G, Strassburg CP, Schrickel JW, Andrié R, Linhart M, Trebicka J.

PLoS One 2018, 13(4): e0195631

DOI: 10.1371/journal.pone.0195631

Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis

Mohr R, Boesecke C, Dold L, Schierwagen R, Schwarze-Zander C, Wasmuth JC, Weisensee I, Rockstroh JK, Trebicka J.

Medicine 2018, 97(17): e0462

DOI: 10.1097/MD.0000000000010462

Registered office

European Foundation for the Study of
Chronic Liver Failure
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain

Legal

Contact us

T +34 93 227 14 00
E efclif@efclif.com

© European Foundation for the Study of Chronic Liver Failure 2024